JP5335419B2 - 治療用組成物および方法 - Google Patents

治療用組成物および方法 Download PDF

Info

Publication number
JP5335419B2
JP5335419B2 JP2008511191A JP2008511191A JP5335419B2 JP 5335419 B2 JP5335419 B2 JP 5335419B2 JP 2008511191 A JP2008511191 A JP 2008511191A JP 2008511191 A JP2008511191 A JP 2008511191A JP 5335419 B2 JP5335419 B2 JP 5335419B2
Authority
JP
Japan
Prior art keywords
further embodiment
compound
macular degeneration
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008511191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540528A5 (https=
JP2008540528A (ja
Inventor
ジョージ シー． チョー
Original Assignee
ザ テキサス エー アンド エム ユニバーシティー システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ テキサス エー アンド エム ユニバーシティー システム filed Critical ザ テキサス エー アンド エム ユニバーシティー システム
Publication of JP2008540528A publication Critical patent/JP2008540528A/ja
Publication of JP2008540528A5 publication Critical patent/JP2008540528A5/ja
Application granted granted Critical
Publication of JP5335419B2 publication Critical patent/JP5335419B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008511191A 2005-05-12 2006-05-04 治療用組成物および方法 Expired - Fee Related JP5335419B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US60/680,998 2005-05-12
US77642606P 2006-02-24 2006-02-24
US60/776,426 2006-02-24
US11/416,773 2006-05-03
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
PCT/US2006/017329 WO2006124324A1 (en) 2005-05-12 2006-05-04 Therapeutic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012159151A Division JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Publications (3)

Publication Number Publication Date
JP2008540528A JP2008540528A (ja) 2008-11-20
JP2008540528A5 JP2008540528A5 (https=) 2012-09-06
JP5335419B2 true JP5335419B2 (ja) 2013-11-06

Family

ID=37431545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008511191A Expired - Fee Related JP5335419B2 (ja) 2005-05-12 2006-05-04 治療用組成物および方法
JP2012159151A Expired - Fee Related JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012159151A Expired - Fee Related JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Country Status (9)

Country Link
US (5) US8088773B2 (https=)
EP (3) EP2508183B1 (https=)
JP (2) JP5335419B2 (https=)
AU (1) AU2006247892B2 (https=)
CA (1) CA2608163C (https=)
DE (1) DE202006020318U1 (https=)
ES (1) ES2598277T3 (https=)
PL (1) PL2508182T3 (https=)
WO (1) WO2006124324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709977A2 (pt) * 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
KR20150032552A (ko) * 2012-06-11 2015-03-26 매큐클리어 인코포레이션 치료 제제 및 치료 방법
JP2015531785A (ja) * 2012-09-13 2015-11-05 シービーエー・ファーマ・インコーポレイテッドＣｂａ Ｐｈａｒｍａ，Ｉｎｃ． テトランドリン医薬製剤及び方法
JP6453216B2 (ja) 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
CA3085331A1 (en) 2017-12-11 2019-06-20 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
JP7089603B2 (ja) * 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429L (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
IT1201151B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
CA2270119A1 (en) * 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Drugs for ameliorating ocular circulatory disorders
AU741525B2 (en) * 1998-03-06 2001-12-06 Board Of Regents, The University Of Texas System Composition and method for treating macular disorders
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES

Also Published As

Publication number Publication date
JP5643263B2 (ja) 2014-12-17
EP1885371A4 (en) 2010-04-07
HK1177419A1 (en) 2013-08-23
EP2508182B1 (en) 2016-07-06
JP2012229257A (ja) 2012-11-22
US20120196868A1 (en) 2012-08-02
US20060276458A1 (en) 2006-12-07
CA2608163A1 (en) 2006-11-23
PL2508182T3 (pl) 2017-05-31
US20130059841A1 (en) 2013-03-07
US20120071485A1 (en) 2012-03-22
EP1885371A1 (en) 2008-02-13
US8088773B2 (en) 2012-01-03
JP2008540528A (ja) 2008-11-20
EP2508182A1 (en) 2012-10-10
EP2508183A1 (en) 2012-10-10
WO2006124324A1 (en) 2006-11-23
US20120115959A1 (en) 2012-05-10
US8318741B2 (en) 2012-11-27
EP2508183B1 (en) 2014-07-09
ES2598277T3 (es) 2017-01-26
AU2006247892A1 (en) 2006-11-23
CA2608163C (en) 2011-10-25
AU2006247892B2 (en) 2010-04-22
DE202006020318U1 (de) 2008-07-31

Similar Documents

Publication Publication Date Title
JP5643263B2 (ja) 治療用組成物および方法
Marquis et al. Management of glaucoma: focus on pharmacological therapy
TWI260327B (en) Pharmaceutical compositions for treating ocular neovascular diseases
US20040216749A1 (en) Vasomodulation during glaucoma surgery
JP2020530470A (ja) 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療
JP2023509336A (ja) 過剰血管新生に関連する眼疾患を治療する化合物
WO2010015672A1 (en) Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye
Polat et al. Combined phacoemulsification and trabectome for treatment of glaucoma
Mandal et al. Glaucoma in aphakia and pseudophakia after congenital cataract surgery
HK1177420A (en) Hydralazine for use in the treatment of age-related macular degeneration
HK1177420B (en) Hydralazine for use in the treatment of age-related macular degeneration
HK1177419B (en) Interleukin-1 blocker for use in the treatment of age-related macular degeneration
Ali et al. Update on congenital glaucoma
Mandal Advances in the Management of Developmental Glaucoma
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
Sampaolesi et al. Medical Therapy in Glaucoma
ManagementManagementnt Evidence-Based Guidelines in Management of Glaucoma
Jindra Open-angle glaucoma: diagnosis and management
De Piedade A One Year Randomized Clinical Trial Of Topical Versus Intracameral Mydriatics In Sustaining Mydriasis During Phacoemulsification Cataract Surgery In Patients Admitted In Kle’s Dr. Prabhakar Kore Hospital And Medical Research Centre Belagavi A One Year Randomized Clinical Trial Of Topical Versus Intracameral Mydriatics In Sustaining Mydriasis During Phacoemulsification Cataract Surgery In Patients Admitted In Kle’s Dr. Prabhakar Kore Hospital And Medical Research Centre Belagavi
Shetty NEOVASCULAR GLAUCOMA
Savage Primary angle-closure glaucoma
Samaddar et al. CHAPTER Glaucoma
Jindra Open-angle glaucoma: diagnosis and therapy
Wright Pediatric Ocular Trauma
CN105796569A (zh) 化合物在制备防治青光眼病的药物中的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120628

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130731

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees